Yao Zhimeng, Du Liang, Xu Min, Li Kai, Guo Haipeng, Ye Guodong, Zhang Dianzheng, Coppes Robert P, Zhang Hao
Cancer Research Center, Shantou University Medical College, Shantou, China.
Department of Biomedical Sciences of Cells and Systems, Section Molecular Cell Biology and Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Front Oncol. 2019 Aug 27;9:816. doi: 10.3389/fonc.2019.00816. eCollection 2019.
Cancer cell plasticity plays critical roles in both tumorigenesis and tumor progression. Metastasis-associated protein 3 (MTA3), a component of the nucleosome remodeling and histone deacetylase (NuRD) complex and multi-effect coregulator, can serve as a tumor suppressor in many cancer types. However, the role of MTA3 in tongue squamous cell cancer (TSCC) remains unclear although it is the most prevalent head and neck cancer and often with poor prognosis. By analyzing both published datasets and clinical specimens, we found that the level of MTA3 was lower in TSCC compared to normal tongue tissues. Data from gene set enrichment analysis (GSEA) also indicated that MTA3 was inversely correlated with cancer stemness. In addition, the levels of MTA3 in both samples from TSCC patients and TSCC cell lines were negatively correlated with SOX2, a key regulator of the plasticity of cancer stem cells (CSCs). We also found that SOX2 played an indispensable role in MTA3-mediated CSC repression. Using the mouse model mimicking human TSCC we demonstrated that the levels of MTA3 and SOX2 decreased and increased, respectively, during the process of tumorigenesis and progression. Finally, we showed that the patients in the MTA3/SOX2 group had the worst prognosis suggesting that MTA3/SOX2 can serve as an independent prognostic factor for TSCC patients. Altogether, our data suggest that MTA3 is capable of repressing TSCC CSC properties and tumor growth through downregulating SOX2 and MTA3/SOX2 might be a potential prognostic factor for TSCC patients.
癌细胞可塑性在肿瘤发生和肿瘤进展中均发挥着关键作用。转移相关蛋白3(MTA3)是核小体重塑和组蛋白去乙酰化酶(NuRD)复合物的一个组成部分以及多效应共调节因子,在多种癌症类型中可作为一种肿瘤抑制因子。然而,MTA3在舌鳞状细胞癌(TSCC)中的作用仍不清楚,尽管它是最常见的头颈癌且预后通常较差。通过分析已发表的数据集和临床标本,我们发现与正常舌组织相比,TSCC中MTA3的水平较低。基因集富集分析(GSEA)的数据也表明MTA3与癌症干性呈负相关。此外,TSCC患者样本和TSCC细胞系中MTA3的水平均与SOX2呈负相关,SOX2是癌症干细胞(CSC)可塑性的关键调节因子。我们还发现SOX2在MTA3介导的CSC抑制中发挥着不可或缺的作用。使用模拟人类TSCC的小鼠模型,我们证明在肿瘤发生和进展过程中,MTA3和SOX2的水平分别降低和升高。最后,我们表明MTA3/SOX2组的患者预后最差,这表明MTA3/SOX2可作为TSCC患者的一个独立预后因素。总之,我们的数据表明MTA3能够通过下调SOX2来抑制TSCC CSC特性和肿瘤生长,并且MTA3/SOX2可能是TSCC患者的一个潜在预后因素。